Related Experiment Video
Updated: Jul 26, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Characterization of p38α autophosphorylation inhibitors that target the non-canonical activation pathway
Lorena González1, Lucía Díaz2, Joan Pous1
1Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, 08028, Barcelona, Spain.
Abstract:
p38α is a versatile protein kinase that can control numerous processes and plays important roles in the cellular responses to stress. Dysregulation of p38α signaling has been linked to several diseases including inflammation, immune disorders and cancer, suggesting that targeting p38α could be therapeutically beneficial. Over the last two decades, numerous p38α inhibitors have been developed, which showed promising effects in pre-clinical studies but results from clinical trials have been disappointing, fueling the interest in the generation of alternative mechanisms of p38α modulation. Here, we report the in silico identification of compounds that we refer to as non-canonical p38α inhibitors (NC-p38i). By combining biochemical and structural analyses, we show that NC-p38i efficiently inhibit p38α autophosphorylation but weakly affect the activity of the canonical pathway. Our results demonstrate how the structural plasticity of p38α can be leveraged to develop therapeutic opportunities targeting a subset of the functions regulated by this pathway.
Insights
New non-canonical p38α inhibitors (NC-p38i) were identified to target specific functions of the p38α pathway. These compounds offer a novel therapeutic strategy by selectively modulating p38α signaling in diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- p38α kinase is crucial for cellular stress responses.
- Dysregulation of p38α signaling is implicated in inflammation, immune disorders, and cancer.
- Previous p38α inhibitors showed limited clinical success, necessitating alternative approaches.
Purpose of the Study:
- To identify novel compounds targeting p38α signaling.
- To explore alternative mechanisms for p38α modulation.
- To develop targeted therapies for p38α-related diseases.
Main Methods:
- In silico identification of non-canonical p38α inhibitors (NC-p38i).
- Biochemical assays to assess inhibitor activity.
- Structural analyses to understand inhibition mechanisms.
Main Results:
- Successfully identified NC-p38i compounds.
- NC-p38i efficiently inhibit p38α autophosphorylation.
- NC-p38i show weak inhibition of the canonical p38α pathway activity.
Conclusions:
- Structural plasticity of p38α can be exploited for therapeutic development.
- NC-p38i represent a promising strategy for selective p38α pathway modulation.
- Targeting specific p38α functions offers new therapeutic opportunities for various diseases.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
The JAK-STAT Signaling Pathway
Amplifying Signals via Enzymatic Cascade
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
The Intrinsic Apoptotic Pathway